Treatment of Acute Lymphoblastic Leukemia in T-Cell (T-Lineage) ALL
T-cell (T-lineage) ALL is a distinct immunophenotypic subtype of acute lymphoblastic leukemia, accounting for approximately 25% of adult ALL cases. The treatment approach for T-lineage ALL follows a structured multi-phase strategy.
Clinical Scenario
This protocol applies to patients with confirmed T-cell (T-lineage) acute lymphoblastic leukemia. Treatment is conducted along lines similar to B-lineage ALL, adapted to the biology of this subtype.
Treatment Approach (Overview)
Management begins with a standard induction phase, followed by an intensification phase that incorporates specific cytotoxic agents — including intensive use of asparaginase, which has demonstrated particular effectiveness in T-lineage disease. The complete multi-phase regimen, sequencing, and eligibility criteria are outlined in the full protocol.
Full regimen details, dosing schedule, and decision algorithm available via the link below.
References
- T-ALL comprises 25% of adult ALL and treatment is similar to that for B-LIN ALL.
- After standard induction, an intensification phase containing CP and AC is usual.
- Intensive use of ASP was highly effective in pediatric T-ALL.
DOI: 10.1182/blood.2023023568
View source ↗